Biomarkers in Plasma and Their Association with Clinical Outcomes in Early-Onset Dementia - Summary - MDSpire

Biomarkers in Plasma and Their Association with Clinical Outcomes in Early-Onset Dementia

  • By

  • Hyemin Jang

  • Sun Min Lee

  • Hee Jin Kim

  • Na-Yeon Jung

  • Henrik Zetterberg

  • Kaj Blennow

  • Liana G. Apostolova

  • So Young Moon

  • Eun-Joo Kim

  • Longitudinal Study of Early-Onset Dementia and Family Members (LEAF) Investigators

  • Kee Hyung Park

  • Hanna Cho

  • Han-Kyeol Kim

  • Yeshin Kim

  • Jae Won Jang

  • Hee Young Kang

  • Sung Hoon Kang

  • Soo Jin Yoon

  • Kwang Ki Kim

  • Hang Rai Kim

  • Sang-Myung Cheon

  • Daye Yoon

  • Kyung Won Park

  • Eun Joo Chung

  • Young Ho Park

  • Jae-Sung Lim

  • Sungyang Jo

  • Geon Ha Kim

  • Jee Hyang Jeong

  • Seong Hye Choi

  • Soo Hyun Cho

  • Hyun-Soo Kim

  • Seung Joo Kim

  • Jay Cheol Kwon

  • Ae Young Lee

  • Juyoun Lee

  • Kyung hun Kang

  • Jaeho Kim

  • Si Eun Kim

  • Hyon-Ah Yi

  • Ahro Kim

  • Ji Yoon Park

  • Ko Woon Kim

  • Yun Su Hwang

  • Min Young Chun

  • Dongwon Yang

  • Bora Yoon

  • Yun Jeong Hong

  • Young Hee Jung

  • Yongsoo Shim

  • Byoung Seok Ye

  • Hyuk Sung Kwon

  • Hee-Jin Kim

  • April 29, 2026

  • 0 min

Share

Objective:

To investigate plasma biomarker trajectories and their associations with clinical outcomes specifically in early-onset Alzheimer disease (EOAD) and frontotemporal dementia (FTD) subgroups.

Key Findings:
  • p-tau217, GFAP, and NfL levels showed distinct trajectories in EOAD and FTD, highlighting their potential role in clinical practice.
  • Higher baseline levels of NfL and GFAP were observed in EOAD compared to late-onset AD.
  • Longitudinal changes in biomarkers were associated with cognitive and functional decline in both EOAD and FTD.
Interpretation:

The study suggests that plasma biomarkers can provide valuable insights into the clinical progression of EOAD and FTD, highlighting their potential for disease monitoring and stratification in clinical trials, which could improve patient management.

Limitations:
  • The study focused only on participants from the LEAF1 phase, limiting generalizability to broader populations.
  • Longitudinal changes in biomarkers were not extensively studied in prior research specific to EOAD and FTD, which may affect the robustness of the findings.
Conclusion:

Plasma biomarkers such as p-tau217, GFAP, and NfL may serve as important tools for differentiating and monitoring clinical outcomes in early-onset dementia, potentially guiding treatment strategies.

Original Source(s)

Biomarkers in Plasma and Their Association with Clinical Outcomes in Early-Onset Dementia

  • by Hyemin Jang, Sun Min Lee, Hee Jin Kim, Na-Yeon Jung, Henrik Zetterberg, Kaj Blennow, Liana G. Apostolova, So Young Moon, Eun-Joo Kim, Longitudinal Study of Early-Onset Dementia and Family Members (LEAF) Investigators , Kee Hyung Park, Hanna Cho, Han-Kyeol Kim, Yeshin Kim, Jae Won Jang, Hee Young Kang, Sung Hoon Kang, Soo Jin Yoon, Kwang Ki Kim, Hang Rai Kim, Sang-Myung Cheon, Daye Yoon, Kyung Won Park, Eun Joo Chung, Young Ho Park, Jae-Sung Lim, Sungyang Jo, Geon Ha Kim, Jee Hyang Jeong, Seong Hye Choi, Soo Hyun Cho, Hyun-Soo Kim, Seung Joo Kim, Jay Cheol Kwon, Ae Young Lee, Juyoun Lee, Kyung hun Kang, Jaeho Kim, Si Eun Kim, Hyon-Ah Yi, Ahro Kim, Ji Yoon Park, Ko Woon Kim, Yun Su Hwang, Min Young Chun, Dongwon Yang, Bora Yoon, Yun Jeong Hong, Young Hee Jung, Yongsoo Shim, Byoung Seok Ye, Hyuk Sung Kwon, Hee-Jin Kim

  • April 29, 2026

Related Content

Evaluating the GRACE voice assistant for dementia care among caregivers and healthcare professionals: An interview study

Housing Insecurity, Incident Geriatric Conditions, and Mortality in Community-Living Older Persons

Glial Fibrillary Acidic Protein and Neurofilament Light Reference Intervals in Healthy Individuals